ArticleBMC oral health2026
Micro/nano-structured titanium surfaces promote endothelial responses and angiogenic activity under zoledronic acid exposure.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDental implants are widely used to restore oral function, maintain mastication, and improve long-term quality of life. However, patients receiving high-dose bisphosphonates (BPs), such as zoledronic acid (ZOL), are considered clinically high-risk due to the potential development of medication-related osteonecrosis of the jaw (MRONJ). Impaired angiogenesis caused by BPs is a key pathogenic factor of MRONJ and an essential role for early wound healing, infection control, and long-term osseointegration of dental implants. Therefore, understanding whether titanium micro/nano-scale topographies can promote angiogenic responses under ZOL exposure is essential for improving implant outcomes in this high-risk population.
methodsTwo micro/nano-structured surfaces were fabricated on selective laser melting (SLM) titanium: (i) SAH: sand-blasted alkali-heated; (ii) SAO: sand-blasting and acid-etching (SLA) followed by anodic oxidation. Conventional SLA surface served as positive control. Under 5 µM ZOL exposure, endothelial morphology, viability, cytoskeletal organization, tube-forming ability, and angiogenic gene and protein expressions were evaluated on different titanium surfaces in vitro. A rat model receiving high-dose intravenous ZOL was used to assess peri-implant vascularization and early osseointegration among mini-implants with different surface topographies in vivo.
resultsMicro/nano-structured (SAH and SAO) surfaces comparably improved endothelial spreading, cytoskeletal integrity, viability, and tube formation compared with SLM and SLA surfaces in the presence of ZOL. Consistently, both SAH and SAO surfaces upregulated the expression of angiogenesis-related genus, including PECAM-1, ICAM-1, vWF, and Ang-1. At the protein level, Ang-1 expression was upregulated on these micro/nano-structured surfaces, while apparent differences in PECAM-1 levels were not observed. In vivo, micro/nano-structured implants showed a higher density of CD31-positive microvessels and a tendency toward improved bone-implant contact and early bone formation despite high-dose ZOL administration.
conclusionsMicro/nano-structured titanium surfaces can enhance endothelial function and promote peri-implant angiogenesis under ZOL exposure challenge. These findings suggest their potential to support better peri-implant vascularization and safer implant rehabilitation for patients receiving high-dose bisphosphonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.